A Single-Dose, Open-Label, Randomized Study of the Comparative Pharmacokinetics of Sublingual TNX-102 2.4 mg at pH 3.5 and 7.1, Oral Cyclobenzaprine 5 mg Tablets, and Intravenous Cyclobenzaprine 2.4 mg in Healthy Adults

Trial Profile

A Single-Dose, Open-Label, Randomized Study of the Comparative Pharmacokinetics of Sublingual TNX-102 2.4 mg at pH 3.5 and 7.1, Oral Cyclobenzaprine 5 mg Tablets, and Intravenous Cyclobenzaprine 2.4 mg in Healthy Adults

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Sep 2014

At a glance

  • Drugs Cyclobenzaprine (Primary) ; Cyclobenzaprine (Primary) ; Cyclobenzaprine (Primary)
  • Indications Fibromyalgia
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Tonix Pharmaceuticals Inc
  • Most Recent Events

    • 06 Jun 2013 Planned End Date changed from 1 Jan 2013 to 1 Jan 2014 as reported by ClinicalTrials.gov.
    • 14 Sep 2012 Planned End Date changed from 1 Sep 2012 to 1 Jan 2013 as reported by ClinicalTrials.gov.
    • 30 Jul 2012 Status changed from recruiting to completed according to a Tonix Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top